Hospital
Prime Healthcare Services Lower Bucks LLC
Prime Healthcare Services Lower Bucks LLC was paid $8.71M by Medicaid between Jan 2018 and Dec 2024, across 89 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES LOWER BUCKS LLC
BRISTOL, PA 19007
BRISTOL, PA 19007
33aNPI1528319621assigned 09/28/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.71M
24GClaims74,198
24DCodes billed89
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#38 of 154
Median peer was paid$2.82M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27 | $4K | |
| 2019 | 298 | $20K | |
| 2020 | 7,403 | $709K | |
| 2021 | 22,780 | $2.37M | |
| 2022 | 12,188 | $1.90M | |
| 2023 | 14,687 | $2.09M | |
| 2024incomplete | 16,815 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 12,097 | 11,511 | $2.84M |
| G0378 | Hospital observation service, per hour | 27% | 1,715 | 1,453 | $2.38M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 8,279 | 7,846 | $1.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 4,877 | 4,654 | $803K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 2,925 | 2,712 | $384K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 1,581 | 1,309 | $214K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 512 | 495 | $110K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 874 | 811 | $98K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 701 | 199 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 675 | 599 | $10K |
| 80053 | Comprehensive metabolic panel | <1% | 4,117 | 3,482 | $10K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 806 | 215 | $9K |
77 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 31 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 449 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 79 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 655 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 42 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 69 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,253 | $5K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 104 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,998 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 254 | $3K |
| 10060 | <1% | 12 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 29 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 247 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,294 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 794 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 327 | $2K |
| OP250 | <1% | 292 | $1K | |
| 84484 | <1% | 689 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 757 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 54 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $962.76 |
| 83690 | <1% | 1,028 | $920.46 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,933 | $878.07 |
| 80320 | <1% | 396 | $797.72 | |
| 73630 | <1% | 140 | $770.09 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $646.40 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 503 | $635.32 |
| 85027 | <1% | 476 | $618.58 | |
| 81025 | <1% | 861 | $603.45 | |
| 81003 | <1% | 1,053 | $491.59 | |
| 72110 | <1% | 26 | $480.27 | |
| 85730 | <1% | 425 | $460.20 | |
| 80329 | <1% | 329 | $458.11 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 246 | $423.72 |
| 81001 | <1% | 727 | $376.12 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 30 | $356.20 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 243 | $336.38 |
| 85610 | <1% | 460 | $318.64 | |
| 83880 | <1% | 77 | $303.52 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 88 | $258.33 |
| 85007 | <1% | 255 | $210.79 | |
| 73610 | <1% | 14 | $204.78 | |
| 83735 | <1% | 396 | $196.53 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,507 | $174.14 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,741 | $165.18 |
| 87040 | <1% | 36 | $140.00 | |
| 83605 | <1% | 52 | $104.00 | |
| 85379 | <1% | 44 | $95.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,103 | $92.97 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 194 | $87.50 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 593 | $79.24 |
| 82550 | <1% | 98 | $71.90 | |
| 99406 | <1% | 20 | $71.65 | |
| J3490 | Unclassified drugs | <1% | 1,408 | $58.52 |
| 82962 | <1% | 221 | $57.20 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 185 | $39.36 |
| 80061 | Lipid panel | <1% | 59 | $30.68 |
| 84100 | <1% | 245 | $26.20 | |
| 87186 | <1% | 12 | $24.00 | |
| 84703 | <1% | 14 | $21.76 | |
| 87077 | <1% | 12 | $21.30 | |
| 86900 | <1% | 29 | $17.23 | |
| 82947 | <1% | 51 | $9.90 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 46 | $7.83 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26 | $7.00 |
| 80076 | <1% | 30 | $6.54 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 153 | $5.11 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 338 | $3.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 337 | $1.76 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22 | $0.24 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 113 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 32 | $0.00 |
| OP257 | 0% | 52 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 23 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 25 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.